期刊
RESPIRATORY MEDICINE
卷 143, 期 -, 页码 74-81出版社
W B SAUNDERS CO LTD
DOI: 10.1016/j.rmed.2018.08.013
关键词
Aerosol propellant; Bronchioles; Chronic obstructive pulmonary disease; Corticosteroids; Inflammation
资金
- Chiesi Farmaceutici, Italy
Objectives: To summarize the evidence of small airways involvement in chronic obstructive pulmonary disease (COPD) pathophysiology, and to evaluate the efficacy of extrafine formulations of inhaled corticosteroids (ICS) in combination with long-acting beta2-agonists (LABAs) in the treatment of COPD. Data source: A search of the PubMed database was conducted using the keywords COPD, small airways, inflammation and extrafine formulation. The search was limited to entries published in English before August 2016. Only studies conducted in humans were considered. Study selection: Publications were included on the basis of relevance. Results: COPD is a common preventable and treatable disease, characterized by persistent and progressive airflow limitation. With improved understanding of COPD pathophysiology, small airways (internal diameter < 2 mm), a well-known major site of COPD-associated inflammation and remodeling, have emerged as a potential target for COPD pharmacologic therapies. The ability of extrafine formulations of ICS in combination with LABAs to achieve central and peripheral lung deposition, and the implications of the enhanced efficacy that this may bring, are discussed by examining findings from the development trials plan of the extrafine formulation of beclometasone dipropionate/formoterol fumarate (Foster (R), Chiesi Farmaceutici, Italy) in patients with COPD. Conclusion: There is an urgent need for improved and reliable techniques for small airways assessment in order to detect early damage, disease progression and response to treatment. Evidence from randomized clinical trials supports the benefits of extrafine ICS/LABA formulations in COPD, real world studies are necessary to confirm this.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据